Abstract
In Reply.— I'm sorry if there was any misunderstanding about the nature of the call my colleague made to Dr Morris. The call was intended specifically to discuss investment opportunities in the biotechnology industry. Our equity research analysts who follow the pharmaceutical and biotechnology industries are among the most highly regarded in the securities industry. Shearson believes that there are many companies that represent attractive investment opportunities in these areas, particularly those distributing erythropoietin. Shearson Lehman Hutton is not aware of any restrictions that preclude physicians from investing in pharmaceutical companies while they prescribe those companies' products.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
